{"schema_version":"alpha-governance-record-v2","alpha_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce","ontology_version":"alpha-governance-ontology-v1","as_of":"2026-10-17T19:35:03.802776+00:00","published_at":"2026-10-17T04:47:19.235235+00:00","section":"board","data":{"state":"PUBLISHED","size":{"value":7,"assertion_class":"alpha_calculated_metric","basis":"Count of published current board seats in this Record. Roster completeness is not asserted.","input_claim_ids":["alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11"]},"chair":null,"lead_independent_director":null,"ceo_chair_combined":null,"independence":{"value":{"independent_directors":5,"directors_with_determination":7,"published_directors":7,"independent_share":0.714},"assertion_class":"alpha_calculated_metric","basis":"Board independence determinations are source facts; the share is computed only over directors with a published determination.","input_claim_ids":["alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11"]},"average_tenure_years":{"value":{"years":5.9,"directors_with_start_date":7},"assertion_class":"alpha_calculated_metric","basis":"Average tenure at the Record as-of time, bounded by appointment end dates; directors without a published start date are excluded.","input_claim_ids":["alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11"]},"committee_load":{"value":{"average_memberships":2,"directors_with_memberships":5},"assertion_class":"alpha_calculated_metric","basis":"Average published committee memberships per current director with at least one published membership.","input_claim_ids":["alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11"]},"skills_coverage":null,"directors":[{"person":{"alpha_id":"alpha:person:adi-mor","name":"Adi Mor","canonical_url":"https://registry.alpha.ac/people/adi-mor"},"current_role":"Director","director_since":"2021-01-01","director_until":null,"status":"current","independent":{"value":false,"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported","valid_from":"2021-01-01","valid_to":null},"board_chair":false,"lead_independent_director":null,"committee_memberships":[],"committee_chairs":[],"skills":[],"fields_not_published":["age","ownership","director_compensation","attendance","overboarding"],"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:alan-moses","name":"Alan Moses","canonical_url":"https://registry.alpha.ac/people/alan-moses"},"current_role":"Director","director_since":"2021-01-01","director_until":null,"status":"current","independent":{"value":true,"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported","valid_from":"2021-01-01","valid_to":null},"board_chair":false,"lead_independent_director":null,"committee_memberships":[{"person":{"alpha_id":"alpha:person:alan-moses","name":"Alan Moses","canonical_url":"https://registry.alpha.ac/people/alan-moses"},"committee_id":"alpha:committee:chemomab-therapeutics-ltd:audit","committee_name":"Audit","role":"member","valid_from":"2021-01-01","valid_to":null,"status":"current","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"],"assertion_class":"source_fact","verification_state":"source_reported"}],"committee_chairs":[],"skills":[],"fields_not_published":["age","ownership","director_compensation","attendance","overboarding"],"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:claude-nicaise","name":"Claude Nicaise","canonical_url":"https://registry.alpha.ac/people/claude-nicaise"},"current_role":"Director","director_since":"2021-01-01","director_until":null,"status":"current","independent":{"value":true,"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported","valid_from":"2021-01-01","valid_to":null},"board_chair":false,"lead_independent_director":null,"committee_memberships":[{"person":{"alpha_id":"alpha:person:claude-nicaise","name":"Claude Nicaise","canonical_url":"https://registry.alpha.ac/people/claude-nicaise"},"committee_id":"alpha:committee:chemomab-therapeutics-ltd:audit","committee_name":"Audit","role":"member","valid_from":"2021-01-01","valid_to":null,"status":"current","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"],"assertion_class":"source_fact","verification_state":"source_reported"}],"committee_chairs":[],"skills":[],"fields_not_published":["age","ownership","director_compensation","attendance","overboarding"],"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:dale-pfost","name":"Dale Pfost","canonical_url":"https://registry.alpha.ac/people/dale-pfost"},"current_role":"Director","director_since":"2021-01-01","director_until":null,"status":"current","independent":{"value":false,"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported","valid_from":"2021-01-01","valid_to":null},"board_chair":false,"lead_independent_director":null,"committee_memberships":[],"committee_chairs":[],"skills":[],"fields_not_published":["age","ownership","director_compensation","attendance","overboarding"],"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:joel-maryles","name":"Joel Maryles","canonical_url":"https://registry.alpha.ac/people/joel-maryles"},"current_role":"Director","director_since":"2021-01-01","director_until":null,"status":"current","independent":{"value":true,"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported","valid_from":"2021-01-01","valid_to":null},"board_chair":false,"lead_independent_director":null,"committee_memberships":[{"person":{"alpha_id":"alpha:person:joel-maryles","name":"Joel Maryles","canonical_url":"https://registry.alpha.ac/people/joel-maryles"},"committee_id":"alpha:committee:chemomab-therapeutics-ltd:audit","committee_name":"Audit","role":"chair","valid_from":null,"valid_to":null,"status":"current","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:joel-maryles","name":"Joel Maryles","canonical_url":"https://registry.alpha.ac/people/joel-maryles"},"committee_id":"alpha:committee:chemomab-therapeutics-ltd:audit-chair-nominating-and-governance","committee_name":"Audit · Chair; Nominating and Governance","role":"member","valid_from":"2021-01-01","valid_to":null,"status":"current","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:joel-maryles","name":"Joel Maryles","canonical_url":"https://registry.alpha.ac/people/joel-maryles"},"committee_id":"alpha:committee:chemomab-therapeutics-ltd:nominating-and-governance","committee_name":"Nominating and Governance","role":"member","valid_from":null,"valid_to":null,"status":"current","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"],"assertion_class":"source_fact","verification_state":"source_reported"}],"committee_chairs":["Audit"],"skills":[],"fields_not_published":["age","ownership","director_compensation","attendance","overboarding"],"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:neil-cohen","name":"Neil Cohen","canonical_url":"https://registry.alpha.ac/people/neil-cohen"},"current_role":"Director","director_since":"2020-01-01","director_until":null,"status":"current","independent":{"value":true,"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported","valid_from":"2020-01-01","valid_to":null},"board_chair":false,"lead_independent_director":null,"committee_memberships":[{"person":{"alpha_id":"alpha:person:neil-cohen","name":"Neil Cohen","canonical_url":"https://registry.alpha.ac/people/neil-cohen"},"committee_id":"alpha:committee:chemomab-therapeutics-ltd:compensation","committee_name":"Compensation","role":"member","valid_from":null,"valid_to":null,"status":"current","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:neil-cohen","name":"Neil Cohen","canonical_url":"https://registry.alpha.ac/people/neil-cohen"},"committee_id":"alpha:committee:chemomab-therapeutics-ltd:compensation-nominating-and-governance-chair","committee_name":"Compensation; Nominating and Governance · Chair","role":"member","valid_from":"2020-01-01","valid_to":null,"status":"current","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:neil-cohen","name":"Neil Cohen","canonical_url":"https://registry.alpha.ac/people/neil-cohen"},"committee_id":"alpha:committee:chemomab-therapeutics-ltd:nominating-and-governance","committee_name":"Nominating and Governance","role":"chair","valid_from":null,"valid_to":null,"status":"current","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"],"assertion_class":"source_fact","verification_state":"source_reported"}],"committee_chairs":["Nominating and Governance"],"skills":[],"fields_not_published":["age","ownership","director_compensation","attendance","overboarding"],"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:nissim-darvish","name":"Nissim Darvish","canonical_url":"https://registry.alpha.ac/people/nissim-darvish"},"current_role":"Director","director_since":"2021-01-01","director_until":null,"status":"current","independent":{"value":true,"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported","valid_from":"2021-01-01","valid_to":null},"board_chair":false,"lead_independent_director":null,"committee_memberships":[{"person":{"alpha_id":"alpha:person:nissim-darvish","name":"Nissim Darvish","canonical_url":"https://registry.alpha.ac/people/nissim-darvish"},"committee_id":"alpha:committee:chemomab-therapeutics-ltd:compensation","committee_name":"Compensation","role":"chair","valid_from":null,"valid_to":null,"status":"current","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"],"assertion_class":"source_fact","verification_state":"source_reported"},{"person":{"alpha_id":"alpha:person:nissim-darvish","name":"Nissim Darvish","canonical_url":"https://registry.alpha.ac/people/nissim-darvish"},"committee_id":"alpha:committee:chemomab-therapeutics-ltd:compensation-chair","committee_name":"Compensation · Chair","role":"member","valid_from":"2021-01-01","valid_to":null,"status":"current","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported"}],"committee_chairs":["Compensation"],"skills":[],"fields_not_published":["age","ownership","director_compensation","attendance","overboarding"],"claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"],"assertion_class":"source_fact","verification_state":"source_reported"}],"fields_not_published":["chair","lead_independent_director","board_type","median_tenure","average_age","refreshment_rate","gender_diversity","geographic_diversity","succession_risk","overboarding","board_interlocks","attendance"]},"claims":[{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:adi-mor","object_label":"Adi Mor","object_source_name_forms":[],"value":"Adi Mor: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:adi-mor","name":"Adi Mor"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:alan-moses","object_label":"Alan Moses","object_source_name_forms":[],"value":"Alan Moses: Director, Audit","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:alan-moses","name":"Alan Moses"},"title":"Director","role_category":"director","committee":"Audit","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:claude-nicaise","object_label":"Claude Nicaise","object_source_name_forms":[],"value":"Claude Nicaise: Director, Audit","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:claude-nicaise","name":"Claude Nicaise"},"title":"Director","role_category":"director","committee":"Audit","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:dale-pfost","object_label":"Dale Pfost","object_source_name_forms":[],"value":"Dale Pfost: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:dale-pfost","name":"Dale Pfost"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:joel-maryles","object_label":"Joel Maryles","object_source_name_forms":[],"value":"Joel Maryles: Director, Audit · Chair; Nominating and Governance","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:joel-maryles","name":"Joel Maryles"},"title":"Director","role_category":"director","committee":"Audit · Chair; Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:neil-cohen","object_label":"Neil Cohen","object_source_name_forms":[],"value":"Neil Cohen: Director, Compensation; Nominating and Governance · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:neil-cohen","name":"Neil Cohen"},"title":"Director","role_category":"director","committee":"Compensation; Nominating and Governance · Chair","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:nissim-darvish","object_label":"Nissim Darvish","object_source_name_forms":[],"value":"Nissim Darvish: Director, Compensation · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:nissim-darvish","name":"Nissim Darvish"},"title":"Director","role_category":"director","committee":"Compensation · Chair","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardCommittee","object_id":null,"object_label":null,"object_source_name_forms":[],"value":"Audit: Chair Joel Maryles; Members Joel Maryles (Chair); Alan Moses; Claude Nicaise","claim_type":"committee_record","predicate_id":"alpha:predicate:committee_record","predicate_version":1,"machine_key":"committee_record","human_label":"Committee Record","governed_predicate":true,"machine_value":{"name":"Audit","canonical_type":"audit","chair":"Joel Maryles","members":[{"display_name":"Joel Maryles","person_slug":"joel-maryles","is_chair":true},{"display_name":"Alan Moses","person_slug":"alan-moses","is_chair":false},{"display_name":"Claude Nicaise","person_slug":"claude-nicaise","is_chair":false}],"source_id":"board_seats"},"corroboration_count":1,"source_claim_count":1,"valid_from":null,"valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":null,"effective_from":null,"effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"source_reported","review_state":"none","confidence":null,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardCommittee","object_id":null,"object_label":null,"object_source_name_forms":[],"value":"Compensation: Chair Nissim Darvish; Members Nissim Darvish (Chair); Neil Cohen","claim_type":"committee_record","predicate_id":"alpha:predicate:committee_record","predicate_version":1,"machine_key":"committee_record","human_label":"Committee Record","governed_predicate":true,"machine_value":{"name":"Compensation","canonical_type":"compensation","chair":"Nissim Darvish","members":[{"display_name":"Nissim Darvish","person_slug":"nissim-darvish","is_chair":true},{"display_name":"Neil Cohen","person_slug":"neil-cohen","is_chair":false}],"source_id":"board_seats"},"corroboration_count":1,"source_claim_count":1,"valid_from":null,"valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":null,"effective_from":null,"effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"source_reported","review_state":"none","confidence":null,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardCommittee","object_id":null,"object_label":null,"object_source_name_forms":[],"value":"Nominating and Governance: Chair Neil Cohen; Members Neil Cohen (Chair); Joel Maryles","claim_type":"committee_record","predicate_id":"alpha:predicate:committee_record","predicate_version":1,"machine_key":"committee_record","human_label":"Committee Record","governed_predicate":true,"machine_value":{"name":"Nominating and Governance","canonical_type":"nominating_governance","chair":"Neil Cohen","members":[{"display_name":"Neil Cohen","person_slug":"neil-cohen","is_chair":true},{"display_name":"Joel Maryles","person_slug":"joel-maryles","is_chair":false}],"source_id":"board_seats"},"corroboration_count":1,"source_claim_count":1,"valid_from":null,"valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":null,"effective_from":null,"effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"source_reported","review_state":"none","confidence":null,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"}],"evidence":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"coverage_state":"PUBLISHED","quality":{"schema_version":"alpha-record-quality-v2","overall":0.84,"status":"strong","publication_readiness":"ready","dimensions":{"identity":1,"coverage":0.5,"freshness":1,"evidence_completeness":1,"source_authority":0.896,"cross_source_agreement":0.75,"temporal_completeness":0.611},"diagnostics":{"published_claims":25,"factual_claims":25,"claims_with_linked_evidence":25,"disputed_claims":0,"conflicts":0,"stale_claims":0,"stale_claim_ids":[],"temporal_claims":18,"temporal_claims_with_valid_from":11,"missing_coverage_sections":["governance","financials","workforce","ownership","ratings"],"missing_expected_claims":["headquarters","official_website","financial_metric","governance_document","ownership","auditor","legal_matter","risk","ai_governance"]},"derivation":"deterministic_record_projection"},"publication":{"state":"PUBLISHED","published_at":"2026-10-17T04:47:19.235235+00:00","observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":"2026-10-17T04:47:19.235235+00:00"},"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":25,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed.","facets":[{"facet":"identity","state":"unclaimed"},{"facet":"evidence","state":"source_reported"},{"facet":"evaluation","state":"not_evaluated"},{"facet":"monitoring","state":null},{"facet":"authority","state":null},{"facet":"freshness","state":"current"}]},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"},"resource":{"uri":"alpha://company/chemomab-therapeutics-ltd/board","section":"board","href":"https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record&section=board","media_type":"application/json","availability":"contract"},"limitations":["Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."]}